Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On
The Company plans to notify the NYSE of its intent to cure the stock price
deficiency and return to compliance with the NYSE continued listing standards.
Under NYSE rules, the Company has a period of six months from receipt of the
NYSE Notification to cure the stock price deficiency and regain compliance with
the NYSE's continued listing standards. The Company can regain compliance at any
time within such cure period if, on the last trading day of any calendar month
during the cure period, the Company has a closing share price of at least
The Company's common stock will continue to be listed and trade on the NYSE during this cure period, subject to the Company's compliance with other NYSE continued listing standards.
Item 7.01 Regulation FD Disclosure.
As required by Section 802.01C, on
The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All statements
contained in this Current Report on Form 8-K that do not relate to matters of
historical fact should be considered forward-looking statements, including
without limitation statements relating to the NYSE's continued listing
standards, the Company's ability to return to and maintain compliance with these
standards and the Company's plans to cure the stock price deficiency. These
forward-looking statements are based on management's current expectations.
Actual results could differ from those projected in any forward-looking
statements due to several risk factors. Such factors include, among others,
risks and uncertainties related to the Company's ability to regain compliance
with the NYSE's continued listing standards within the applicable cure period;
the Company's ability to continue to comply with the applicable NYSE continued
listing standards; the Company's limited operating history; the Company's
significant losses incurred since inception and expectation to incur significant
additional losses for the foreseeable future; the Company's ability to continue
as a going concern; the Company's ability to successfully execute or achieve the
benefits of its strategic prioritization and other cost saving measures; the
development of the Company's initial product candidates, upon which its business
is highly dependent; the impact of the COVID-19 pandemic on the Company's
operations and clinical activities; the Company's need for additional funding
and its cash runway; the lengthy, expensive, and uncertain process of clinical
drug development, including uncertain outcomes of clinical trials and potential
delays in regulatory approval; the Company's ability to maintain its
relationships with its third party vendors; and protection of the Company's
proprietary technology, intellectual property portfolio and the confidentiality
of its trade secrets. These and other important factors discussed under the
caption "Risk Factors" in the Company's Quarterly Reports on Form 10-Q, Annual
Reports on Form 10-K, and other filings with the
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued bySQZ Biotechnologies Company onJanuary 18, 2023 . 104 Cover Page Interactive Data File (embedded with the Inline XBRL document).
--------------------------------------------------------------------------------
© Edgar Online, source